DEXCOM INC (DC4.DE) Stock Price, Quote, News and Overview
FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR
DC4.DE Quote, Performance and Key Statistics
FRA:DC4 (3/7/2025, 7:00:00 PM)
73.72
-1.54 (-2.05%)
The current stock price of DC4.DE is 73.72 EUR. In the past month the price decreased by -13%. In the past year, price decreased by -32.91%.
DC4.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 28.95 | 217.38B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 79.29 | 192.03B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 68.9 | 166.86B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 39.01 | 133.56B | ||
| 2M6.DE | MEDTRONIC PLC | 17.45 | 110.81B | ||
| BOX.DE | BECTON DICKINSON AND CO | 16.31 | 60.33B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 23.49 | 59.08B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 26.43 | 37.76B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 18.17 | 23.74B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 18.14 | 23.71B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 18.06 | 23.59B | ||
| BIM.PA | BIOMERIEUX | 33.32 | 13.65B |
Related stock screener links
About DC4.DE
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 9,600 full-time employees. The company went IPO on 2005-04-14. The firm enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The firm is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The firm is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.
Company Info
DEXCOM INC
6340 Sequence Dr
San Diego CALIFORNIA US
Employees: 9550
Company Website: https://www.dexcom.com/
Investor Relations: https://investors.dexcom.com
Phone: 18582000200
DEXCOM INC / DC4.DE FAQ
What is the stock price of DEXCOM INC today?
The current stock price of DC4.DE is 73.72 EUR. The price decreased by -2.05% in the last trading session.
What is the ticker symbol for DEXCOM INC stock?
The exchange symbol of DEXCOM INC is DC4 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is DC4.DE stock listed?
DC4.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for DEXCOM INC stock?
32 analysts have analysed DC4.DE and the average price target is 99.34 EUR. This implies a price increase of 34.76% is expected in the next year compared to the current price of 73.72. Check the DEXCOM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DEXCOM INC worth?
DEXCOM INC (DC4.DE) has a market capitalization of 28.81B EUR. This makes DC4.DE a Large Cap stock.
How many employees does DEXCOM INC have?
DEXCOM INC (DC4.DE) currently has 9550 employees.
What are the support and resistance levels for DEXCOM INC (DC4.DE) stock?
DEXCOM INC (DC4.DE) has a support level at 73.71 and a resistance level at 84.97. Check the full technical report for a detailed analysis of DC4.DE support and resistance levels.
Is DEXCOM INC (DC4.DE) expected to grow?
The Revenue of DEXCOM INC (DC4.DE) is expected to grow by 14.43% in the next year. Check the estimates tab for more information on the DC4.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DEXCOM INC (DC4.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DC4.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DC4.DE, evaluating the profitability, health, valuation and growth aspects
- DEXCOM INC (DC4.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DEXCOM INC (DC4.DE) Sales and EPS estimates to see what analysts future expectations are.
- DEXCOM INC (DC4.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DEXCOM INC (DC4.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- DEXCOM INC (DC4.DE) Stock Chart to make your own analysis
- DEXCOM INC (DC4.DE) Latest news and press-releases to stay up to date.
Does DEXCOM INC (DC4.DE) stock pay dividends?
DC4.DE does not pay a dividend.
When does DEXCOM INC (DC4.DE) report earnings?
DEXCOM INC (DC4.DE) will report earnings on 2025-04-23, after the market close.
What is the Price/Earnings (PE) ratio of DEXCOM INC (DC4.DE)?
The PE ratio for DEXCOM INC (DC4.DE) is 48.18. This is based on the reported non-GAAP earnings per share of 1.53 and the current share price of 73.72 EUR. Check the full fundamental report for a full analysis of the valuation metrics for DC4.DE.
DC4.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DC4.DE. When comparing the yearly performance of all stocks, DC4.DE is a bad performer in the overall market: 92.24% of all stocks are doing better.
DC4.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE. While DC4.DE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
DC4.DE Financial Highlights
Over the last trailing twelve months DC4.DE reported a non-GAAP Earnings per Share(EPS) of 1.53. The EPS increased by 9.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.29% | ||
| ROA | 8.89% | ||
| ROE | 27.4% | ||
| Debt/Equity | 0.62 |
DC4.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to DC4.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 24.7% and a revenue growth 14.43% for DC4.DE